MyMD Pharmaceuticals Enrolls First Individual in Phase 2 Medical Trial of MYMD-1 as a Treatment for Delaying Aging as well as Extending Healthy And Balanced Lifespan

MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Firm”), a clinical stage pharmaceutical business devoted to expanding healthy and balanced life expectancy, today revealed that the initial person has been enrolled in the Firm’s Phase 2 professional test of lead prospect MYMD-1, an oral immune regulatory authority drug, as a therapy for delaying aging and increasing healthy lifespan.

The key endpoint for the Phase 2 double-blind, placebo-controlled scientific test is to attain a decrease in the circulating degrees of (TNF-α), growth death aspect receptor I (TNFRI) and also IL-6. TNF-α and also IL-6 are the healthy proteins in the body that create swelling and also help activate the procedure of aging. The second actions of the trial will be the safety and security, tolerability, as well as pharmacokinetics in this population of people.

” In a Stage 1 professional test of MYMD-1, we demonstrated the medication’s statistically considerable efficacy in lowering levels of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has actually authorized TNF-α reduction as the primary endpoint for our Phase 2 research study, which our team believe placements us well for a successful Stage 2 result,” said Chris Chapman, M.D., Head Of State, Director as well as Chief Medical Police Officer of MyMD. “The initiation of person enrollment in this study breakthroughs our objective to slow the aging process, prevent loss of muscle cells in aging, limit frailty, and prolong healthy and balanced lifespan.”

MyMD has actually stated that there are no FDA-approved drugs for treating aging problems as well as expanding healthy lifespan humans, a market expected to be a minimum of $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are the most prescribed medicines by revenue, a worldwide market of roughly $40 billion annually,2 as well as, according to Nature Aging journal,3 a slowdown in aging that would enhance life span by one year is worth $38 trillion and by ten years is worth $367 trillion.

In addition to aging, MYMD-1’s unique action in managing the body immune system and also dealing with chronic swelling is being established for the treatment of autoimmune disease, including rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes mellitus, and inflammatory digestive tract illness.

” We plan to begin composing methods for a Phase 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The climbing prevalence of rheumatoid joint inflammation as well as various other autoimmune and also inflammatory diseases are driving demand for TNF preventions like MYMD-1, as well as we believe our by mouth administered medication with extremely low toxicity would certainly be disruptive to the $60 billion market for RA if accepted by the FDA for this indication.”

Rheumatoid arthritis impacts around 40 million people around the world.4.

Concerning MYMD-1.

Initially established for autoimmune conditions, MYMD-1’s primary purpose is to reduce the aging process, protect against sarcopenia and also frailty, and also extend healthy life expectancy. Due to the fact that it can go across the blood-brain barrier as well as access to the main nerve system (CNS), MYMD-1 is likewise placed to be a feasible treatment for brain-related conditions. Its device of action and also effectiveness in diseases including numerous sclerosis (MS) and also thyroiditis have actually been researched through partnerships with several scholastic institutions. MYMD-1 is additionally revealing pledge in pre-clinical research studies as a potential therapy for article- COVID-19 problems and also as an anti-fibrotic and also anti-proliferation restorative.

MYMD-1 has shown performance in pre-clinical researches in regulating the body immune system by carrying out as a careful inhibitor of growth necrosis factor-alpha (TNF-α), a vehicle driver of chronic inflammation. Unlike other therapies, MYMD-1 has been received these pre-clinical researches to precisely block TNF-α when it becomes overactivated in autoimmune diseases and also cytokine tornados, but not obstruct it from doing its regular work of being a very first responder to any type of routine kind of moderate infection. MYMD-1’s simplicity of oral application is another differentiator contrasted to presently offered TNF-α blockers, all of which require shipment by shot or mixture. No accepted TNF prevention has ever before been dosed orally. Additionally, the drug is not immunosuppressive and also has actually not been shown to cause the major side effects common with standard therapies that deal with inflammation.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical company dedicated to extending healthy life expectancy, is concentrated on creating two unique therapeutic platforms that treat the sources of illness as opposed to just attending to the signs. MYMD-1 is a medicine system based upon a scientific phase little particle that manages the body immune system to control TNF-α, which drives persistent swelling, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, boost long life, and also deal with autoimmune conditions and COVID-19- associated anxiety. The Business’s second medicine system, Supera-CBD, is being created to treat persistent pain, dependency as well as epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and is being created to resolve and also improve upon the quickly growing CBD market, which includes both FDA authorized medications as well as CBD items not presently regulated as drugs. To learn more, visit www.mymd.com.